WASHINGTON (AP) — Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S. The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisk’s diabetes drug semaglutide. In company-funded studies, participants taking Wegovy had average weight loss of 15%, about 34 […]